Loading…
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $3M | $-103M | $-115M | $-94M | -60.8% | -38.2% | - |
| 2024 | $5M | $-89M | $-103M | $-73M | -57.6% | -20.7% | - |
| 2023 | $6M | $-95M | $-111M | $-65M | -62.8% | -0.5% | - |
| 2022 | $6M | $-91M | $-105M | $-98M | -38.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 5.75 | 5.72 | 4.53 | 2.80 |
| Operating Expense | 112.50 | 99.90 | 113.42 | 128.22 |
| Operating Income | -106.75 | -94.18 | -108.89 | -125.42 |
| EBITDA | -91.29 | -95.46 | -89.08 | -103.16 |
| EBIT | -104.39 | -109.46 | -102.47 | -114.91 |
| Pretax Income | -105.36 | -110.47 | -103.04 | -115.11 |
| Tax Provision | -0.46 | 0.10 | 0.07 | 0.07 |
| Net Income | -104.90 | -110.57 | -103.11 | -115.18 |
| Net Income Common Stockholders | -104.90 | -110.57 | -103.11 | -115.18 |
| Total Expenses | 112.50 | 99.90 | 113.42 | 128.22 |
| Interest Expense | 0.97 | 1.01 | 0.56 | 0.21 |
| Research And Development | 58.91 | 48.07 | 63.86 | 81.42 |
| Selling General And Administration | 40.55 | 37.83 | 36.17 | 35.06 |
| Normalized EBITDA | -91.29 | -74.12 | -89.08 | -108.26 |
| Normalized Income | -104.90 | -93.71 | -103.11 | -119.21 |
| Basic EPS | -1.15 | -1.20 | -0.94 | -0.84 |
| Diluted EPS | -1.15 | -1.20 | -0.94 | -0.84 |
| Tax Effect Of Unusual Items | 0 | -4.48 | 0 | 1.07 |
| Tax Rate For Calcs | 0 | 0.21 | 0.21 | 0.21 |
| Total Unusual Items | 0 | -21.34 | 0 | 5.10 |
| Total Unusual Items Excluding Goodwill | 0 | -21.34 | 0 | 5.10 |
| Net Income From Continuing Operation Net Minority Interest | -104.90 | -110.57 | -103.11 | -115.18 |
| Reconciled Depreciation | 13.10 | 14 | 13.39 | 11.74 |
| Net Interest Income | -0.97 | -1.01 | -0.56 | -0.21 |
| Net Income From Continuing And Discontinued Operation | -104.90 | -110.57 | -103.11 | -115.18 |
| Total Operating Income As Reported | -106.75 | -115.52 | -108.89 | -120.32 |
| Diluted Average Shares | 90.85 | 92.03 | 110.24 | 136.78 |
| Basic Average Shares | 90.85 | 92.03 | 110.24 | 136.78 |
| Diluted NI Availto Com Stockholders | -104.90 | -110.57 | -103.11 | -115.18 |
| Otherunder Preferred Stock Dividend | 0 | 0 | 0 | 0 |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -104.90 | -110.57 | -103.11 | -115.18 |
| Net Income Continuous Operations | -104.90 | -110.57 | -103.11 | -115.18 |
| Other Income Expense | 2.36 | -15.28 | 6.42 | 10.51 |
| Other Non Operating Income Expenses | 2.36 | 6.06 | 6.42 | 5.41 |
| Special Income Charges | 0 | -21.34 | 0 | 5.10 |
| Impairment Of Capital Assets | 0 | 21.34 | 0 | 0 |
| Restructuring And Mergern Acquisition | 0 | 0 | 0 | -5.10 |
| Net Non Operating Interest Income Expense | -0.97 | -1.01 | -0.56 | -0.21 |
| Interest Expense Non Operating | 0.97 | 1.01 | 0.56 | 0.21 |
| Depreciation Amortization Depletion Income Statement | 13.04 | 14 | 13.39 | 11.74 |
| Depreciation And Amortization In Income Statement | 13.04 | 14 | 13.39 | 11.74 |
| Operating Revenue | 5.75 | 5.72 | 4.53 | 2.80 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Absci Corporationthis co. | ABSI | $732M | - | 3.77 | -60.8% | -5.15 |
| ARS Pharmaceuticals, Inc. | SPRY | $778M | - | 6.81 | -149.9% | -3.94 |
| BioAge Labs, Inc. | BIOA | $749M | - | 2.32 | -29.6% | -5.11 |
| Castle Biosciences, Inc. | CSTL | $734M | - | 1.53 | -5.1% | -224.72 |
| CBLL | CBLL | $729M | - | 4.65 |
| -34.4% |
| -10.30 |
| Allogene Therapeutics, Inc. | ALLO | $726M | - | 1.65 | -65.3% | -1.79 |
| Gyre Therapeutics, Inc. | GYRE | $713M | 367.50 | 6.33 | 3.5% | 46.81 |
| Enhabit, Inc. | EHAB | $704M | - | 1.31 | -0.8% | 13.72 |
| Solid Biosciences Inc. | SLDB | $694M | - | 3.09 | -96.8% | -2.97 |
| Peer Median | - | 367.50 | 2.70 | -32.0% | -3.46 | |